{
  "nctId": "NCT06532357",
  "briefTitle": "A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.",
  "officialTitle": "Evaluation of Satisfaction With Rimegepant and Triptans Utilizing Migraine Buddy Retrospective Data",
  "protocolDocument": {
    "nctId": "NCT06532357",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2024-06-27",
    "uploadDate": "2025-06-05T10:37",
    "size": 820815,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT06532357/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 1536,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2024-06-09",
    "completionDate": "2024-06-10",
    "primaryCompletionDate": "2024-06-10",
    "firstSubmitDate": "2024-07-29",
    "firstPostDate": "2024-08-01"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications).\n* Male or female participants with migraine\n* Having consented to the anonymous use of their data for research\n* Currently using Nurtec and/or triptans to treat migraine attacks\n\nExclusion Criteria:\n\n* Users who did not report using either medication for which they complete the survey within 60 days prior to the survey.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants Classified as Per Responses for Satisfaction of Pain Intensity",
        "description": "Participants responded about satisfaction with treatment for pain intensity using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.",
        "timeFrame": "Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day"
      },
      {
        "measure": "Number of Participants Classified as Per Responses for Satisfaction With of Attack Duration",
        "description": "Participants responded about satisfaction with of attack duration using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.",
        "timeFrame": "Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day"
      },
      {
        "measure": "Number of Participants Classified as Per Responses for Satisfaction With Speed of Action",
        "description": "Participants responded about satisfaction with speed of action using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.",
        "timeFrame": "Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day"
      },
      {
        "measure": "Number of Participants Classified as Per Responses for Satisfaction With Migraine-Induced Cognitive Impact",
        "description": "Participants responded about satisfaction with migraine-Induced cognitive impact using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.",
        "timeFrame": "Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day"
      },
      {
        "measure": "Number of Participants Classified as Per Responses for Satisfaction With Relief of Other Symptoms",
        "description": "Participants responded about satisfaction with relief of other symptoms using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment. Other symptoms included following parameters: photophobia, phonophobia, nausea, vomiting, sensitivity to light/sound/odors).",
        "timeFrame": "Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day"
      },
      {
        "measure": "Number of Participants Classified as Per Responses for Satisfaction of Tolerability",
        "description": "Participants responded about satisfaction of tolerability using following responses: extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied, extremely dissatisfied. Based on participants responses, the respondents were grouped into those who were satisfied (reported extremely satisfied/ satisfied/ slightly satisfied), neutral (reported neither satisfied nor dissatisfied) or dissatisfied (reported slightly dissatisfied/ dissatisfied/ extremely dissatisfied) with the treatment.",
        "timeFrame": "Up to 60 days post last usage of treatment (from retrospective data collection period of 7 months); available retrospective data was evaluated in this observational study of a single day"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 6,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 79,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:54.564Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}